{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:18:54Z","timestamp":1794129534328,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114172","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T11:38:13Z","timestamp":1718451493000},"page":"114172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma"],"prefix":"10.1016","volume":"207","author":[{"given":"Rik J.","family":"Verheijden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke H.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine C.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk E.","family":"Putker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie P.G.R.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A.P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen J.B.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel W.","family":"Hehenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle L.E.","family":"Doornebosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe","family":"Verhaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franchette W.P.J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Llobell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre T.J.","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Takeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Salvador","family":"Garc\u00eda Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Lidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mick J.M.","family":"van Eijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djura","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette","family":"Labots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karijn P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2024.114172_bib1","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114172_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114172_bib3","first-page":"1","article-title":"Clinical and translational attributes of immune-related adverse events","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114172_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114172_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.114172_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211058393","article-title":"Adverse events induced by nivolumab and ipilimumab combination regimens","volume":"14","author":"Somekawa","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2024.114172_bib7","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.114172_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114172_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.114172_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.ejca.2024.114172_bib11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114172_bib12","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114172_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis","volume":"13","author":"Dall\u2019Olio","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.ejca.2024.114172_bib14","first-page":"1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"Npj Precis Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2024.114172_bib15","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with Anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.114172_bib16","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of Anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2024.114172_bib17","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114172_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaoncol.2023.0103","article-title":"Steroid dose and duration, immortal time bias, and survival after high-grade immune-related adverse events\u2014reply","volume":"9","author":"van Not","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.114172_bib19","unstructured":"ECOG-ACRIN Cancer Research Group. ECOG-ACRIN Cancer Research Group. [cited 2023 Jun 22]. ECOG Performance Status Scale. Available from: \u3008https:\/\/ecog-acrin.org\/resources\/ecog-performance-status\u3009\/."},{"issue":"8","key":"10.1016\/j.ejca.2024.114172_bib20","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: american joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114172_bib22","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, 13e","article-title":"Adrenocorticotropic hormone, adrenal steroids, and the adrenal cortex","author":"Schimmer","year":"2017"},{"issue":"5","key":"10.1016\/j.ejca.2024.114172_bib23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamaoncol.2023.0100","article-title":"Steroid dose and duration, immortal time bias, and survival after high-grade immune-related adverse events","volume":"9","author":"Reid","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114172_bib24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/apt.17201","article-title":"Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis","volume":"56","author":"Dahl","year":"2022","journal-title":"Aliment Pharm Ther"},{"issue":"11","key":"10.1016\/j.ejca.2024.114172_bib25","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3390\/cancers15113041","article-title":"Better late than never: the impact of steroidal treatment on the outcome of melanoma patients treated with immunotherapy","volume":"15","author":"Bar-Hai","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejca.2024.114172_bib26","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/cncr.34742","article-title":"The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study","volume":"129","author":"Lev-Ari","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.114172_bib27","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/cancers15092538","article-title":"Steroid-refractory immune-related adverse events induced by checkpoint inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ejca.2024.114172_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007557","article-title":"Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events","volume":"11","author":"Gente","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2024.114172_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2024.114172_bib30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ejca.2024.114172_bib31","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"issue":"7756","key":"10.1016\/j.ejca.2024.114172_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejca.2024.114172_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe?","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheuma"},{"key":"10.1016\/j.ejca.2024.114172_bib34","article-title":"Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology","volume":"193","author":"Alouani","year":"2023","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"10.1016\/j.ejca.2024.114172_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.114172_bib36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11912-022-01241-z","article-title":"Immune checkpoint inhibitor rechallenge and resumption: a systematic review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.114172_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9520","article-title":"Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab","volume":"41","author":"Maloney","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114172_bib38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:24:30Z","timestamp":1786969470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"alternative-id":["S0959804924008281"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114172","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114172"}}